Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SQ-22031 eye drops in moderate to severe dry eye disease
CTR20253183Phase 2Active
- Sponsor
- Xingqi Eye Medicine
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SQ-22031 in dry eye syndrome (DED), sponsored by Xingqi Eye Medicine. Started Aug 2025; status: active.
02
Drugs
SQ-22031
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20253183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253183.